TT-OAD2 free base_product_DataBase

Bioactivity	TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment[1][2].
Target	EC50: 5 nM (GLP-1 receptor)
Invitro	TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner in HEK293A cells[1].
In Vivo	TT-OAD2 (3 mg/kg; intravenous injection; male human GLP-1 receptor knock-in and knockout mice) treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice[1]. Animal Model:
Name	TT-OAD2 free base
CAS	1246826-07-2
Formula	C50H47Cl2N3O6
Molar Mass	856.83
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Zhao P, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436. [2]. Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1.

PeptideDB